• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在未预先接触头孢他啶/阿维巴坦的情况下出现产KPC-8感染：头孢他啶/阿维巴坦耐药KPC变体感染的威胁。

Emergence of KPC-8-producing infection without prior exposure to ceftazidime/avibactam: the threat of infections by ceftazidime/avibactam-resistant KPC variants.

作者信息

Mateo-Vargas María Alejandra, Rodríguez-Pallares Salud, Arca-Suárez Jorge, López-Cerero Lorena, Rodríguez-Iglesias Manuel, Galán-Sánchez Fátima

机构信息

Departamento de Biomedicina, Biotecnología y Salud Pública, Universidad de Cádiz, Cadiz, Spain.

Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña (Spain), A Coruña, Spain.

出版信息

Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0149424. doi: 10.1128/aac.01494-24. Epub 2025 Apr 22.

DOI:10.1128/aac.01494-24
PMID:40261073
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12135529/
Abstract

infections caused by ceftazidime/avibactam-resistant KPC variants are rarely reported. We characterize the evolution of a KPC-8-producing strain involved in a primary infection without previous ceftazidime/avibactam treatment. During a 15-month follow-up, changes in carbapenem susceptibility due to porin alterations were observed, remaining susceptible to meropenem/vaborbactam, imipenem/relebactam, and cefiderocol. High- and low-permeability recombinant isolates analysis revealed that, unlike the widespread ceftazidime/avibactam-resistant variant KPC-31, KPC-8 confers ceftazidime/avibactam resistance without decreasing carbapenemase activity.

摘要

由对头孢他啶/阿维巴坦耐药的KPC变体引起的感染鲜有报道。我们对一株产生KPC-8的菌株的进化进行了表征，该菌株参与了未经头孢他啶/阿维巴坦治疗的原发性感染。在15个月的随访期间，观察到由于孔蛋白改变导致碳青霉烯敏感性发生变化，该菌株对美罗培南/巴罗巴坦、亚胺培南/瑞来巴坦和头孢地尔仍然敏感。高渗透性和低渗透性重组分离株分析表明，与广泛存在的对头孢他啶/阿维巴坦耐药的变体KPC-31不同，KPC-8赋予头孢他啶/阿维巴坦耐药性，而不会降低碳青霉烯酶活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bdf/12135529/2201081545f9/aac.01494-24.f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bdf/12135529/475f57584b70/aac.01494-24.f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bdf/12135529/4ef70d959f7e/aac.01494-24.f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bdf/12135529/dc233436ee8a/aac.01494-24.f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bdf/12135529/2201081545f9/aac.01494-24.f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bdf/12135529/475f57584b70/aac.01494-24.f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bdf/12135529/4ef70d959f7e/aac.01494-24.f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bdf/12135529/dc233436ee8a/aac.01494-24.f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bdf/12135529/2201081545f9/aac.01494-24.f004.jpg

相似文献

1
Emergence of KPC-8-producing infection without prior exposure to ceftazidime/avibactam: the threat of infections by ceftazidime/avibactam-resistant KPC variants.在未预先接触头孢他啶/阿维巴坦的情况下出现产KPC-8感染：头孢他啶/阿维巴坦耐药KPC变体感染的威胁。
Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0149424. doi: 10.1128/aac.01494-24. Epub 2025 Apr 22.
2
Mutant prevention concentrations, resistance evolution dynamics, and mechanisms of resistance to imipenem and imipenem/relebactam in carbapenem-susceptible isolates showing ceftazidime/avibactam resistance.对头孢他啶/阿维巴坦耐药的碳青霉烯敏感菌株中，亚胺培南及亚胺培南/瑞来巴坦的突变预防浓度、耐药性演变动态及耐药机制
Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0112024. doi: 10.1128/aac.01120-24. Epub 2024 Nov 15.
3
In vitro activity and genomic characterization of KPC-producing Klebsiella pneumoniae clinical blood culture isolates resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam: an Italian nationwide multicentre observational study (2022-23).产KPC的肺炎克雷伯菌临床血培养分离株对头孢他啶/阿维巴坦、美罗培南/瓦博巴坦、亚胺培南/瑞来巴坦耐药的体外活性及基因组特征：一项意大利全国多中心观察性研究（2022 - 23年）
J Antimicrob Chemother. 2025 Feb 3;80(2):583-592. doi: 10.1093/jac/dkae450.
4
In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series.产 KPC 肺炎克雷伯菌感染中新型β-内酰胺/β-内酰胺酶抑制剂合剂耐药性的体内发展：病例系列。
Eur J Clin Microbiol Infect Dis. 2024 Dec;43(12):2407-2417. doi: 10.1007/s10096-024-04958-w. Epub 2024 Oct 10.
5
Evolution of ceftazidime-avibactam resistance driven by variation in to during treatment of ST11-K64 hypervirulent .在ST11-K64高毒力肺炎克雷伯菌治疗期间，由blaKPC至blaNDM变异驱动的头孢他啶-阿维巴坦耐药性演变
Front Cell Infect Microbiol. 2025 Jun 6;15:1607127. doi: 10.3389/fcimb.2025.1607127. eCollection 2025.
6
ICU environment as a reservoir of KPC-ST307-Klebsiella pneumoniae high-risk clone resistant to ceftazidime-avibactam.重症监护病房环境是携带对头孢他啶-阿维巴坦耐药的肺炎克雷伯菌高风险克隆KPC-ST307的储存库。
Sci Rep. 2025 Aug 12;15(1):29486. doi: 10.1038/s41598-025-14987-w.
7
ARGONAUT-III and -V: susceptibility of carbapenem-resistant and multidrug-resistant to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime.ARGONAUT-III 和 -V：碳青霉烯类耐药和多重耐药对双环硼酸β-内酰胺酶抑制剂替加环素与头孢吡肟联合用药的敏感性。
Antimicrob Agents Chemother. 2024 Sep 4;68(9):e0075124. doi: 10.1128/aac.00751-24. Epub 2024 Aug 12.
8
Whole-genome sequencing characterisation of a new KPC-245 variant-carrying Klebsiella pneumoniae strain isolated from a transplanted patient and resistant to ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam.从一名移植患者中分离出的携带新型KPC-245变体的肺炎克雷伯菌菌株的全基因组测序特征，该菌株对头孢他啶/阿维巴坦、美罗培南/瓦博巴坦和亚胺培南/瑞来巴坦耐药。
J Glob Antimicrob Resist. 2025 May;42:229-233. doi: 10.1016/j.jgar.2025.03.006. Epub 2025 Mar 18.
9
Within-host resistance evolution of ST15 Klebsiella pneumoniae in an ICU immunosuppressed patient under antibiotic pressure of polymyxins, ceftazidime-avibactam, and meropenem.在多粘菌素、头孢他啶-阿维巴坦和美罗培南的抗生素压力下，一名重症监护病房免疫抑制患者体内ST15肺炎克雷伯菌的宿主内耐药性演变
Int J Antimicrob Agents. 2025 Jun 19;66(4):107554. doi: 10.1016/j.ijantimicag.2025.107554.
10
Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil.巴西住院患者血流感染碳青霉烯类耐药肺炎克雷伯菌的新型β-内酰胺/β-内酰胺酶抑制剂组合的药敏评估。
J Glob Antimicrob Resist. 2024 Sep;38:247-251. doi: 10.1016/j.jgar.2024.06.007. Epub 2024 Jun 25.

本文引用的文献

1
Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.头孢地尔肟与新型β-内酰胺/β-内酰胺酶抑制剂组合对高、低通透性条件下表达单种和双种β-内酰胺酶的同源大肠埃希菌的活性。
Int J Antimicrob Agents. 2024 May;63(5):107150. doi: 10.1016/j.ijantimicag.2024.107150. Epub 2024 Mar 19.
2
Replacement of KPC-producing pandemic lineages and dissemination of plasmids associated with antimicrobial resistance determinants during inpatient's hospitalization.住院期间产KPC的大流行谱系的更替以及与抗菌药物耐药性决定因素相关质粒的传播。
J Glob Antimicrob Resist. 2023 Mar;32:85-87. doi: 10.1016/j.jgar.2022.10.016. Epub 2022 Nov 8.
3
Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview.耐头孢他啶-阿维巴坦的肺炎克雷伯菌碳青霉烯酶变异体：进化概述。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0044722. doi: 10.1128/aac.00447-22. Epub 2022 Aug 18.
4
CARB-ES-19 Multicenter Study of Carbapenemase-Producing e and From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3.CARB-ES-19：一项针对来自西班牙所有省份的产碳青霉烯酶肠杆菌科细菌的多中心研究揭示了高风险克隆株如ST307/OXA-48和ST512/KPC-3的跨地区传播。
Front Microbiol. 2022 Jun 30;13:918362. doi: 10.3389/fmicb.2022.918362. eCollection 2022.
5
Widespread emergence of OmpK36 loop 3 insertions among multidrug-resistant clones of Klebsiella pneumoniae.广泛出现的肺炎克雷伯菌耐多药克隆的 OmpK36 环 3 插入。
PLoS Pathog. 2022 Jul 11;18(7):e1010334. doi: 10.1371/journal.ppat.1010334. eCollection 2022 Jul.
6
Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect.碳青霉烯类耐药肠杆菌科（CRE）对头孢地尔和头孢他啶-阿维巴坦的交叉耐药性及其接种物效应。
Clin Microbiol Infect. 2021 Aug;27(8):1172.e7-1172.e10. doi: 10.1016/j.cmi.2021.04.016. Epub 2021 Apr 26.
7
Interplay among Different Fosfomycin Resistance Mechanisms in Klebsiella pneumoniae.肺炎克雷伯菌中不同磷霉素耐药机制的相互作用。
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01911-20.
8
Ceftazidime-Avibactam Resistance Associated with Increased Gene Copy Number Mediated by pKpQIL Plasmid Derivatives in Sequence Type 258 .头孢他啶-阿维巴坦耐药与 258 型序列型中由 pKpQIL 质粒衍生物介导的基因拷贝数增加有关。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.01816-19.
9
Effects of KPC Variant and Porin Genotype on the Activity of Meropenem-Vaborbactam against Carbapenem-Resistant .KPC 变体和孔蛋白基因型对美罗培南-沃班坦对碳青霉烯类耐药 的活性的影响。
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02048-18. Print 2019 Mar.
10
Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Carbapenemase-Producing : A Case Report and Review of Literature.产碳青霉烯酶菌株中头孢他啶-阿维巴坦耐药的出现及碳青霉烯类药物敏感性的恢复：一例报告及文献综述
Open Forum Infect Dis. 2017 Jul 1;4(3):ofx101. doi: 10.1093/ofid/ofx101. eCollection 2017 Summer.